Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients

Christopher G. Willett, Gregory Y. Lauwers, Dan G. Duda et al.|Journal of Clinical Oncology|2005

Cited by 419